ABSTRACT
The Tamil Nadu Air Pollution and Health Effects study (TAPHE-2) aims to evaluate the relationship between air pollution and birth outcome in a rural-urban cohort of 300 pregnant women. Due to COVID-19 related lockdowns, some TAPHE-2 activities were delayed;however, continuous indoor and outdoor air quality data were collected in and around Chennai, India. We report here the impact of graded COVID-19 lockdown on indoor particulate matter (PM2.5 and PM10) levels based on calibrated data from affordable real-time PM sensors called atmos™ and ambient PM levels from publicly available regulatory monitors. The study period was between 11 March and 30 June 2020 (i.e., 100 days of continuous monitoring), which coincided with four phases of a nationwide graded lockdown. Field calibration coefficients for the atmos PM were derived by collocating them with reference-grade PM monitors. The normalized root mean square error (NRMSE) of the atmos hourly PM2.5 (PM10) improved from 41% to 15% (33% to 18%) after applying the field calibration coefficients. Lockdowns resulted in significant reductions in indoor and ambient PM levels, with the highest reduction observed during lockdown phase 2 (L2) and phase 3 (L3). Reductions as high as 70%, 91%, and 62% were observed in ambient PM2.5, indoor PM2.5, and indoor PM10 relative to pre-lockdown levels (PL), respectively. The indoor PM2.5/PM10 ratio decreased during the lockdown, suggesting a decline in the fine mode dominance in PM10. The indoor-to-outdoor (I/O) ratios in PM2.5 marginally increased during L1, L2, and L3 phases compared to that of PL levels, suggesting an uneven reduction in indoor and ambient PM2.5 levels during the lockdown. © The Author's institution.
ABSTRACT
Hydroxychloroquine, an antimalarial, is being used worldwide for prophylaxis and treatment of Corona virus disease-19 (COVID-19). Though the drug is commonly used in many chronic inflammatory diseases for protracted periods, its safety in the new indication is still under scrutiny. Therefore, this institute based study sought to assess the acute adverse effects of hydroxychloroquine among in-house health care professionals who were taking the drug for COVID-19 prophylaxis. A questionnaire seeking information on the use of the drug was prepared and disseminated electronically to the target population. The responses were also received electronically and analysed. The participants (n=54) had taken prophylaxis for 1-7 weeks. The most common adverse effects in the cohort were nausea (02) and skin rash (02). The total number of adverse effects reported by the participants was 08. One incidence each of gastric upset (01), dizziness (01), pain abdomen (01), and chest tightness (01) was reported. None of the adverse effects were serious. Our study indicates that the prophylactic weekly single dose of hydroxychloroquine is not associated with any serious adverse effects within 1-7 weeks of initiation. Elucidation of the long term and chronic adverse effects, if any, requires further studies.